Hereditary Cancer PGT-M Screening in Georgia: Process & Gene Blocking Guide

I. Physician Decision Logic: Why Patients with Hereditary Cancer Need PGT-M Screening in Georgia

In a reproductive clinic, when a BRCA1 gene mutation carrier or a Lynch syndrome patient comes for consultation, the core question is not "can I get pregnant," but "how can I ensure the next generation does not carry this pathogenic gene."

Although third-generation IVF (PGT) technology is available in China, some hospitals have a lengthy approval process for monogenic diseases (PGT-M) and require that at least one partner be clearly affected. In contrast, fertility centers in Georgia have a more open attitude toward PGT-M for hereditary tumors—as long as you provide authoritative genetic test reports (e.g., BRCA1/2, MLH1, MSH2, MSH6, PMS2, APC, RET), you can directly enter the cycle. Additionally, Georgia allows HLA typing of embryos (if a family member requires a bone marrow transplant), which is particularly important for certain hereditary cancer syndrome families.

Physician's Decision Tree

• Step 1: Confirm the Pathogenic Gene — Must be a known, clearly pathogenic mutation with an autosomal dominant (e.g., BRCA1/2), autosomal recessive (e.g., MUTYH-associated polyposis), or X-linked (e.g., certain lymphoproliferative syndromes) inheritance pattern. If it is a de novo mutation or there are no other affected family members, verification is required first.
• Step 2: Assess Ovarian Function — PGT-M requires a sufficient number of blastocysts (typically ≥3) to have healthy embryos for transfer. Women with AMH <1.0 ng/mL and antral follicle count <5 are advised to undergo egg retrieval to accumulate embryos first.
• Step 3: Choose the Country — Georgia's advantages include: no waiting lists, genetic testing and embryo biopsy can be completed in the same center, no legal restrictions on embryo genetic screening, and costs about one-third of those in the US. Disadvantages include: need for remote communication, and the qualifications of some center laboratories need verification.

II. Direct Answers: The Complete Picture of Hereditary Cancer PGT-M Screening in Georgia

III. Most Overlooked Details: Validity of Genetic Test Reports and Linkage Analysis

Many patients believe that once they have undergone genetic testing, they can directly proceed with PGT-M. In reality, if the DNA of the proband (affected relative) in the family cannot be obtained, or if the mutation site is in a high-GC region or copy number variation region, family verification of the patient and spouse may be required first. Inexpensive exome sequencing (covering only exonic regions) may miss large deletions, and laboratories in Georgia typically require detailed mutation site information and chromosomal coordinates.

Key Points: Before going to Georgia, ensure that the genetic report issued domestically includes:

• HGVS nomenclature (e.g., NM_007294.4:c.68_69delAG)
• Pathogenicity classification (according to ACMG standards)
• Parental verification results (if de novo mutation, parental samples needed)
• English version for coordination with Georgian laboratory

Differences Between the Two Countries

• China: PGT-M requires ethical approval, taking 1-3 months; only clearly identified pathogenic genes can be tested, and non-medical HLA typing is not allowed.
• Georgia: No approval needed; all hereditary tumor genes (e.g., BRCA, MLH1, MSH2, APC, RET, VHL, NF1) can be included in the testing panel; simultaneous testing for chromosomal aneuploidy (PGT-A) is allowed but at an additional cost.
• USA/Japan: More mature technology, but costs 2-3 times higher than Georgia, and visa requirements are more stringent.

IV. Detailed Process: From Domestic Preparation to Embryo Transfer

Phase 1: Domestic Foundation Work (1-2 months)

• Confirm genetic mutation: Complete genetic counseling and testing at a tertiary hospital, obtain reports in Chinese and English.
• Fertility assessment: AMH, antral follicle count, semen analysis, infectious disease screening (HIV, hepatitis B, syphilis, etc.).
• Passport processing: Check passport validity at least 3 months in advance; Georgia requires passport validity of at least 6 months upon entry.
• Hospital selection: Compare 2-3 Georgian fertility centers, focusing on whether they have PGT-M qualifications (e.g., collaboration with tertiary hospital genetics laboratories).

Phase 2: Remote Registration and Ovarian Stimulation Protocol (1 month)

• Video consultation: Doctor designs protocol based on AMH, age, and past stimulation history. Common protocols include antagonist or mild stimulation.
• Medication preparation: Some medications can be purchased domestically (with a prescription), but it is recommended to buy them at local pharmacies in Georgia to avoid customs issues.
• Visa and tickets: Georgia offers e-visas (30 days) for Chinese citizens, or visa on arrival. A stay of 25-30 days is recommended.

Phase 3: Egg Retrieval and Embryo Culture (2-3 weeks)

• Arrive on day 2 of menstruation, start stimulation (about 10-12 days).
• Egg retrieval: Puncture under local anesthesia, simultaneous sperm collection.
• ICSI fertilization: Since PGT-M requires embryo biopsy, all should use intracytoplasmic sperm injection.
• Blastocyst culture: Culture to day 5-6, biopsy of trophectoderm cells (about 5-10 cells).
• Vitrification: All blastocysts are frozen, awaiting genetic test results.

Phase 4: Genetic Testing and Transfer (6-8 weeks)

• Biopsied cells sent to laboratory (usually local in Georgia, or to partner labs in Ukraine/Israel).
• Testing content: Target pathogenic gene mutation + high-precision linkage analysis + PGT-A (optional).
• Result report: After 4-6 weeks, genetic report for each embryo, indicating whether it is a carrier of the pathogenic gene and whether it is euploid.
• Frozen-thawed transfer: Natural cycle or hormone replacement cycle, transfer 1-2 healthy embryos.

V. Special Situations: Recurrent Cancer Patients, Prior Chemoradiotherapy, Advanced Age

• Prior Chemoradiotherapy: Ovarian function may be severely compromised; consider egg/embryo cryopreservation first. If amenorrhea has occurred after chemotherapy, assess for antral follicles. Some patients may consider egg donation.
• Post-breast cancer endocrine therapy: Tamoxifen inhibits endometrial thickness; consult with oncologist about stopping medication for 3 months. If not possible, consider surrogacy (legal in Georgia, but requires additional legal procedures).
• Male BRCA2 carriers: BRCA2 mutation is associated with prostate cancer risk, but male fertility is usually normal. Monitor sperm DNA fragmentation index; if high, it may affect blastocyst development.
• Age >42 years: Egg yield significantly decreases; consider 2-3 egg retrieval cycles to accumulate embryos before unified biopsy to avoid failure due to lack of healthy embryos in a single cycle.

VI. Frequently Asked Questions

Q: Does embryo biopsy harm the embryo?
The biopsy extracts trophectoderm cells that will develop into the placenta, with no direct impact on the inner cell mass (which becomes the fetus). Current data show no significant difference in implantation rates between biopsied euploid blastocysts and non-biopsied blastocysts.

Q: What if all embryos carry the pathogenic gene?
Theoretically, different embryos segregate independently during meiosis; unless both parents carry the same mutation (very low probability), there will always be non-carrier embryos. However, if only 1-2 blastocysts are available, there may be no healthy embryos. In such cases, egg or embryo donation can be considered.

Q: How to choose a hospital in Georgia?
Prioritize centers with formal PGT laboratories (e.g., collaborating with Invitae, Genomic Prediction) and Chinese-speaking patient coordinators. Do not rely solely on official websites; check actual biopsy success rates through third-party patient forums or testimonials.

Q: Can I do only PGT-A without PGT-M?
No. PGT-A only screens for chromosomal number abnormalities, not single-gene mutations. Patients with hereditary cancer must undergo PGT-M to block the condition. However, both can be done simultaneously for an additional cost (approximately $3,000-$5,000).

VII. Risk Reminders

• Genetic testing carries a risk of false negatives (e.g., due to allele dropout), so prenatal diagnosis (amniocentesis) is still required after transfer.
• Fewer laboratories in Georgian fertility centers have CAP or ISO15189 certification; request qualification documents from the testing laboratory.
• If mosaicism is detected after embryo biopsy (some cells carry the mutation, some are normal), clinical management is controversial; consult your doctor in advance about whether to transfer.
• Overseas medical care lacks domestic regulatory oversight; purchase travel insurance covering assisted reproduction and sign a clear medical contract (bilingual Chinese and English).

General principle: Blocking hereditary cancer through IVF screening is a mature medical practice, but success highly depends on ovarian reserve, quality of genetic reports, and embryo number. Before departure, ensure a comprehensive evaluation with a reproductive geneticist to identify the most suitable path for you.